BIRC6 AS A NOVEL THERAPEUTIC TARGET IN TRIPLE NEGATIVE BREAST CANCER

GÓMEZ BERGNA SANTIAGO MANUEL; FARINA HERNÁN G.; MARCHESINI ABRIL; ROMANOWSKI VÍCTOR; GOTTARDO MARÍA FLORENCIA; PIDRE MATIAS LUIS

Buenos Aires

Congreso; LXV REUNIÓN ANUAL DE LA SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC); 2020

SAIC

BIRC6 (baculoviral IAP repeat-containing protein 6) is a member of the inhibitors of apoptosis protein family thought to play an important role in the progression or chemoresistance of many cancers. The aim of this study was to investigate the role of BIRC6 in triple negative breast cancer (TNBC).Firstly, we analyzed BIRC6 mRNA expression levels and Copy Number Variations (CNV) in three Breast Cancer databases (TCGA) using cBioPortal and USCSXena platforms comparing clinical and molecular attributes. In addition, we analyzed the BIRC6 expression in murine (F3II) and human (MDA-MB-231) TNBC cell lines by immunofluorescence. Moreover, we used a recombinant baculovirus able to silence BIRC6 previously constructed in our lab. Then, we determined apoptosis levels in F3II cells by TUNEL.Our bioinformatics results showed that there was a differential expression of BIRC6 in cancer samples compared to normal samples (normal= -0,372±0,395, cancer= 0,113±1,055; t-test, p